ASCO 2023 Poster: Androgen-deprivation therapy and risk of dementia in patients with prostate cancer:Clinical outcomes from real-world data.

[rsgdmd]

Conclusion: This is the largest real-world study describing the association between ADT and the risk of dementia, including over 600 thousand prostate cancer patients. The risk of dementia was significantly higher in patients on ADT, with a 60% increased risk. The highest risk was witnessed with GnRH antagonists (degarelix), with a 92% increased risk. Interestingly, the increased risk of dementia in ADT groups was observed only among whites but not in African Americans. Possible causes of this discrepancy include socioeconomic disparities, bias that resulted in underdiagnosis, or biological differences.

[Shorehousejam]

great…what I’m on Firmagon (degarelix)

[Tall_Allen]

See my reply:

healthunlocked.com/advanced...